Back to Daily DR Market Summary

StreetAccount Summary - Asian Market Preview: Nikkei Futures +0.64%, Hang Seng Futures +0.01%, ASX SPI 200 +0.61%, S&P Futures +0.37%

Nov 24 ,2024

  • Synopsis:

    • Asian markets set for positive start to Monday trade. Futures signaling opening gains in Japan as ASX advances in initial trade. Hang Seng futures flat. S&P 500 futures strengthening after indexes capped off solid weekly gain. Australian and New Zealand bonds rallying, taking cues from Treasury curve flattening. Dollar seeing mild losses DXY surged to two-year high. Crude and gold steady after also staging weekly rally. Bitcoin pulling back from $100K.

    • Trump rounded out his cabinet over weekend with Scott Bessent's nomination as Treasury Secretary the most important for markets. Bessent viewed as market friendly nomination who had also received backing of Wall Street. Early takeaways highlighting his focus on fiscal restraint (tax cuts with offsets). Bessent in favor of tariffs but considered less of an ideologue.

    • China tech space under sustained pressure with Hang Seng tech index and Nasdaq Golden Dragon index entering bear market, down ~20% from early October highs, weighed down by combination of China stimulus disappointment, still-weak economic momentum, and geopolitical uncertainty. Soft earnings also driving bearish sentiment after latest results underlined an uncertain revenue outlook amid tepid consumer spending.

    • Economic activity picks up this week across Asia with central banks a focus. RBNZ expected to cut by 50 bp with outside chance of 75 bp reduction. BOK expected to remain hold following October's cut. RBA Governor Bullock's policy bias will be scrutinized in a speech. In terms of data, China PMIs forecast to show further pickup in factory activity this month. Tokyo core inflation forecast to have risen back to 2% target.

  • Pre-open Company News:

    • 1848.HK -- China Aircraft Leasing Group Holdings sells six aircraft; completion expected before end of March 2025

    • 600062.CH -- China Resources Double-Crane Pharmaceutical receives NMPA approval for clinical trial of semaglutide injection as biosimilar for use of weight management

    • 002352.CH -- S.F. Holding prices 170M-share Hong Kong IPO at HK$34.3/share

    • 658.HK -- China High Speed Transmission Equipment Group seeks legal advice on ~CNY6.64B receivables incurred without board approval

    • 542907.IN -- Prince Pipes & Fittings downgraded to neutral from buy at Goldman Sachs

    • 688777.CH -- SUPCON Technology completes up to CNY200M share buyback announced on 2-Jul

    • Goldman Sachs downgrades 000725.CH, 002236.CH, 002456.CH, and 300661.CH

    • 9926.HK -- Akeso Inc initiated buy at Pacific Securities (22-Nov, timing uncertain)

    • 551.HK -- Yue Yuen Industrial (Holdings) initiated buy at SWS Research

  • On Deck:

    • China:

      • Earnings:

        • Hesai Group (HSAI)

    • Hong Kong:

      • Earnings:

        • Want Want China Holdings (151.HK), Tianli International Holdings (1773.HK)

    • Japan:

      • Economic:

        • 14:00 JST: Leading Index (Final); consensus

    • Australia:

      • Earnings:

        • Webjet Group (WJL.AU), Aroa Biosurgery (ARX.AU)

    • New Zealand:

      • Earnings:

        • Gentrack Group (GTK.NZ)

    • Singapore:

      • Economic:

        • 08:00 SST: GDP NSA Y/Y (Final); consensus +4.1%

  • Market Data:

    • Gold (Dec 24): +$7.10 or +0.26% to $2719.30

    • WTI Crude (Jan 25): +$0.11 or +0.15% to $71.35

    • $-¥: (0.64) or (0.41%) to 154.1040

    • $-KRW: (0.94) or (0.07%) to 1403.5000

    • A$-$: +0.00 or +0.60% to 0.6542

    • $-INR: (0.00) or (0.00%) to 84.4295

    • $-CNY: (0.00) or (0.02%) to 7.2415

  • If you would like to receive the Asian Market Preview daily, please search for Asia Pre-Market Updates in Alert Manager.

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE